<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-85148</identifier>
<setSpec>0014-2565</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Prevalence of metabolic syndrome in patients with stable coronary disease: therapeutic objectives and utilization of cardiovascular drugs</dc:title>
<dc:description xml:lang="en">Objective. The achievement of the therapeutic objectives in patients with ischemic heart disease and metabolic syndrome is unknown. This study has aimed to evaluate whether the prevalence of risk factors, the prescription rate of evidence-based cardiovascular therapies and the attainment of therapeutic goals differ in coronary patients with and without the metabolic syndrome (MS). Methods. A multicenter, cross-sectional study carried out with the participation of 7,600 patients with stable coronary heart disease (mean age 65.3 years, 82% males, 37.7% with MS) attended in primary care. Data on drug prescription and goal attainment were extracted from clinical records. MS was defined according to the National Cholesterol Education Program (NCEP) criteria. Results. Patients with MS had a higher prevalence of cardiovascular risk factors and cardiovascular disease. They also had a higher prescription rate of blood-pressure lowering drugs, statins and antidiabetic agents, without differences in the rate of use of antithrombotics and beta-blockers. After adjusting for cardiovascular risk factors and co-morbidity, only fibrates and angiotensin II receptor blockers were used more frequently in MS patients. A lower percentage of subjects with MS achieved therapeutic goals of LDL cholesterol (23.4% vs 27.7%, P&lt;.001), blood pressure (29.1% vs 52.2%, P&lt;.001) and, in diabetics, of glycated hemoglobin (54.7% vs 75.9%, P&lt;.001). Conclusion. Patients with stable coronary disease and MS do not reach therapeutic objectives as frequently as those without MS, in spite of receiving a higher amount of cardiovascular drugs(AU)</dc:description>
<dc:creator>Lahoz, C</dc:creator>
<dc:creator>Tranche, S</dc:creator>
<dc:creator>López-Rodríguez, I</dc:creator>
<dc:creator>Taboada, M</dc:creator>
<dc:creator>Sánchez-Zamorano, M. A</dc:creator>
<dc:creator>Monteiro, B</dc:creator>
<dc:creator>Martín-Jadraque, R</dc:creator>
<dc:creator>Mostaza, J. M</dc:creator>
<dc:creator>Mantilla, M. T</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo. La consecución de objetivos terapéuticos en pacientes con cardiopatía isquémica crónica y síndrome metabólico (SM) es desconocida. El objetivo del estudio fue analizar en pacientes con enfermedad coronaria estable si la prevalencia de los factores de riesgo, la utilización de fármacos cardiovasculares y la consecución de objetivos terapéuticos eran diferentes en función de la presencia o no del SM. Métodos. Estudio transversal multicéntrico en el que participaron 7.600 sujetos con enfermedad coronaria estable atendidos en Atención Primaria. Para el diagnóstico del SM se utilizaron los criterios del National Colesterol Educational Programm &#150; Adult Treatment Programm III (NCEP-ATP III). Resultados. La edad media fue 65,3 años (hombres, 82%). El 37,7% cumplía criterios de SM. Los pacientes con SM tenían una significativa mayor prevalencia e intensidad de los factores de riesgo, así como una mayor comorbilidad cardiovascular. Además, utilizaban con mayor frecuencia antihipertensivos, hipolipemiantes e hipoglucemiantes, no existiendo diferencias en antitrombóticos y betabloqueantes. Tras ajustar por los factores de riesgo y la comorbilidad solo los fibratos y los antagonistas del receptor de la angiotensina II eran utilizados más frecuentemente por los pacientes con SM. Los objetivos terapéuticos de colesterol-LDL (23,4% versus 27,7%, p&lt;0,001), de presión arterial (29,1% versus 52,2%, p&lt;0,001) y de hemoglobina glucada en diabéticos (54,7% versus 75,9%, p&lt;0,001), se alcanzaron menos frecuentemente en los pacientes con SM. Conclusión. Los pacientes con enfermedad coronaria estable y SM alcanzan unos objetivos terapéuticos con menor frecuencia que los enfermos sin SM, a pesar de recibir una mayor cantidad de fármacos(AU)</dc:description>
<dc:source>Rev Clin Esp;211(1): 1-8, ene.2011. tab, ilus</dc:source>
<dc:identifier>ibc-85148</dc:identifier>
<dc:title xml:lang="es">Prevalencia de síndrome metabólico en pacientes con enfermedad coronaria estable: objetivos terapéuticos y utilización de fármacos cardiovasculares</dc:title>
<dc:subject>^d28599</dc:subject>
<dc:subject>^d30650^s22080</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d3346^s22053</dc:subject>
<dc:subject>^d2359^s22057</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d30650^s22012</dc:subject>
<dc:subject>^d36032^s22080</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d24772</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d24584</dc:subject>
<dc:subject>^d28596</dc:subject>
<dc:subject>^d24572</dc:subject>
<dc:subject>^d11756^s22074</dc:subject>
<dc:subject>^d2358^s22073</dc:subject>
<dc:subject>^d30650^s22016</dc:subject>
<dc:subject>^d53393</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:type>article</dc:type>
<dc:date>201101</dc:date>
</metadata>
</record>
</ibecs-document>
